All Abuzz About CLL: Exploring Fixed-Duration Regimens and Cardiotoxicity Management

Target Audience
The target audiences for the proposed HCP activity are community neurologists, neuromuscular specialists, immunologists, PCPs, hospitalists, emergency physicians, APNs, RNs, pharmacists.

Program Overview
Differentiating chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) from other immune-mediated inflammatory neuropathies can be challenging for clinicians. Misdiagnoses are common and can lead to poor outcomes for patients. However, newly revised guidelines for CIDP offer an opportunity to address barriers to accurate diagnoses and appropriate treatments.

Join an expert panel of neurologists and representatives from the GBS|CIDP Foundation International to discuss disease aspects/variants, simplify accurate diagnoses, and offer evidence-based guidance on treatment options and selections. Panelists will cover the place of imaging technologies in diagnosis, recognition of CIDP based on symptoms, and testing recommendations in the 2021 guidelines. Clinicians will leave the activity better able to work with their patients to individualize treatments and incorporate emerging agents and immunoglobulin formulations as they are approved.

Educational Objectives
Upon completion of this activity, participants should be better able to:

Integrate the 2021 European Academy of Neurology/Peripheral Nerve Society guidelines into the diagnosis and treatment of CIDP
Summarize how new diagnostic criteria and use of imaging technology will improve the diagnosis of CIDP and its variants
Formulate individualized treatment plans with the patient based on updated recommendations, patients’ quality of life, and measures of disability and impairment
Summarize rationale for the need and data to date with new approaches to the treatment of CIDP, including new immunoglobulin formulations and FcRn receptor-targeted agents